Syndivia presenting at MedFIT 2018

Syndivia’s CEO, Dr Oleksanr Koniev, will be giving a talk at MedFIT 2018, Strasbourg, France, on Wednesday, 27th June 2018. MedFIT is the leading European partnering event dedicated to innovation partnerships and the main marketplace for early-stage investment in the fields of medical technology, diagnostic and digital health.


Syndivia wins the France Tech Transfer Invest Award

PARIS, France, February 2, 2017 -- Syndivia wins the France Tech Transfer Invest Award during a Tech Tour event that took place in Paris on 1-2 February 2017. The event is a collaboration between the SATT, Tech Tour, Bpifrance and its EuroQuity platform and aims to efficiently and effectively support French tech companies to meet and engage with international investors and corporate partners.
For more information on the event visit:


OGD2 Pharma and Syndivia launch collaboration to develop an ADC targeting the O-acetyl-GD2 cancer antigen

NANTES, France, Sept. 6, 2016 (GLOBE NEWSWIRE) -- OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer therapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2), today announces a collaboration with Syndivia SAS, a biotechnology company that provides best-in-class bioconjugation technologies for the development of Antibody-Drug Conjugates (ADC).

Full press release available at:

Syndivia receives the EU’s Horizon 2020 grant

The European Commission has named Syndivia as one of the new Phase 1 beneficiaries of the European Union's SME Instrument. SME Instrument is a highly competitive grant that supports close-to-market activities, with the aim to give a strong boost to breakthrough innovation. Highly innovative SMEs with a clear commercial ambition and a potential for high growth and internationalisation are the prime target. The SME Instrument Phase 1 grant is aimed to fund the feasibility assessment of Syndivia's next-generation targeted cancer therapies.


Job opening announcement | Research Assistant in Mass Spectrometry

Syndivia is looking for a highly motivated candidate for a PhD project on characterisation of antibody-drug conjugates by mass spectrometry.
The responsibilities of the candidate will include:

  • Development of high-throughput analytical methods for determination of drug-to antibody ratio (DAR)
  • Identification of conjugation sites in site-specific and classical antibody-drug conjugates
  • Collaborating with outside groups on project-related studies.

An ideal candidate will have knowledge and experience in:

  • Native mass spectrometry
  • Proteomics

Please, send your CV, a motivation letter and names of two referees to